DelMar Pharmaceuticals Profile

0.65
USD 0.011291  1.77%
65%

Key Fundamentals

DelMar Pharmaceuticals Against Markets

DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada. DelMar Pharmaceuticals operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 4 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
DelMar Pharmaceuticals SEC Filings
DelMar Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameDelMar Pharmaceuticals
President CEO, DirectorJeffrey BachaView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Analyst Consensus
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
LocationBRITISH COLUMBIA CANADA
Business Address999 West Broadway
ExchangeBATS Exchange
CUSIP247078108
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.delmarpharma.com
Phone604 629 5989
CurrencyUSD - US Dollar

DelMar Pharmaceuticals Corporate Directors

John Bell Independent Director
William Garner Director
Erich Mohr Independent Director
Additionally see Investing Opportunities. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">